Chemomab Therapeutics Ltd.
CMMB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $18 | $17 | $6 |
| G&A Expenses | $0 | $7 | $12 | $6 |
| SG&A Expenses | $0 | $7 | $12 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $15 | $0 | $0 | $0 |
| Operating Expenses | $15 | $25 | $29 | $12 |
| Operating Income | -$15 | -$25 | -$29 | -$12 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $0 | -$0 |
| Pre-Tax Income | -$14 | -$24 | -$28 | -$12 |
| Tax Expense | $0 | $0 | -$1 | $0 |
| Net Income | -$14 | -$24 | -$28 | -$12 |
| % Margin | – | – | – | – |
| EPS | -3.12 | -8.22 | -9.68 | -4.8 |
| % Growth | 62% | 15.1% | -101.7% | – |
| EPS Diluted | -3.12 | -8.22 | -9.68 | -4.8 |
| Weighted Avg Shares Out | 4 | 3 | 3 | 3 |
| Weighted Avg Shares Out Dil | 4 | 3 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$14 | -$25 | -$28 | -$12 |
| % Margin | – | – | – | – |